Joint application:
- with methotrexate at a dose of 15 mg per week or more: the hemolytic cytotoxicity of methotrexate is increased (the renal clearance of methotrexate and methotrexate is replaced by salicylates in association with blood plasma proteins);
- with anticoagulants, for example, heparin: increased risk of bleeding due to a violation of the function of platelets, damage to the mucosa of the gastrointestinal tract, the displacement of anticoagulants (indirect) from the connection with blood plasma proteins:
- with other non-steroidal anti-inflammatory drugs: as a result of synergistic interaction, the risk of ulcers and bleeding from the stomach and duodenum increases;
- with uricosuric medicines, for example, benzbromarone: reduces the uricosuric effect;
- with digoxin: the concentration of digoxin is increased due to a decrease in renal excretion:
- with hypoglycemic drugs: increased hypoglycemic effect of hypoglycemic drugs due to hypoglycemic effect of acetylsalicylic acid;
- with preparations of thrombolytics group: the fibrinolytic effect of the latter increases and the risk of bleeding increases;
- with glucocorticosteroids, excluding hydrocortisone, Used as a substitute for Addison's disease: when using glucocorticosteroids, the concentration of salicylates in the blood decreases due to an increase in the excretion of the latter;
- with inhibitors of the angiotensin-converting enzyme: reduced glomerular filtration by inhibiting the synthesis of prostaglandins and, as a consequence, reduced anti-hypertensive effect;
- with valproic acid: increases the toxicity of the shafts] of rye acid:
- with glucocorticosteroids, ethanol (alcoholic beverages) and ethanol containing medicines: the risk of damage to the mucous membrane of the gastrointestinal tract increases, the risk of developing gastrointestinal bleeding increases;
- intensifies the effects of narcotic analgesics, indirect anticoagulants and antiaggregants, sulfonamides (including co-trimoxazole - increases their activity and toxicity), triiodothyronine (increases activity and increases the risk of side effects of the latter);
- reduces the effect of antihypertensive drugs, diuretics (spironolactone, furosemide);
- increases the concentration of barbiturates, lithium salts in plasma;
- antacids containing magnesium and / or aluminum slow down and worsen the absorption of acetylsalicylic acid;
- Myelotoxic drugs increase the manifestation of hematotoxicity of the drug.